CHAMPS Oncology

Based in New Jersey, US and founded in 2007 by David Sidransky, CHAMPS Oncology aka CHAMPS, operates as a data-driven research company provide platform for drug development through clinical stages. In March 2021, Q-Centrix, LLC, a portfolio company of TPG, acquired CHAMPS Oncology. The company has revenue of USD 54. 1 million as of April 2022.

The company is public traded with ticker CSBR and with an employee count 185 as of April 2022. The company offers lumin analytic engine that datasets such as clinical response, tumor phenotypes, patient metadata profiles, and molecular profiles with analytics and visualizations applied to this dataset to understand tumor cell biology deriving novel insights. The firm offers research software such as model select, cell line select, and lumin bioinformatics. The luminous bioinformatics analytic and visualization software enables cancer biologists to harness the power of computational science in tools.

The firm offers cell line select which is a searchable database containing over 100 Human cancer cell lines, including characterization datasets such as gene mutations identified through Whole Exome Sequencing (WES) and gene expression levels quantified using RNASeq technology. CHAMPS provides a model select which is a searchable database that contains essential data on our PDX tumor models.